Acute Respiratory Distress Syndrome (ARDS) Market
The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033
The Business Research Company's Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024 identifies growing prevalence of pneumonia as the major driver for the Acute Respiratory Distress Syndrome (ARDS) market's growth in the forecast period. Pneumonia is an infection that affects one or both lungs, causing the lungs' air sacs, or alveoli, to fill up with fluid or pus. Pneumonia causes an inflammatory reaction in the lungs, increasing blood vessel permeability and fluid leakage into the alveoli.
The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2024 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.
The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%.
Download Free Sample Of Acute Respiratory Distress Syndrome (ARDS) Market Report - www.thebusinessresearchcompany.com/sample_request?id=13005&type=smp
Major competitors in the Acute Respiratory Distress Syndrome (ARDS) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH.
A key trend in the Acute Respiratory Distress Syndrome (ARDS) market includes major companies operating in the acute respiratory distress syndrome (ARDS). Aviptadil is a synthesized vasoactive intestinal peptide (VIP) that binds specifically to receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an India-based pharmaceutical manufacturing company, launched Aviptadil to treat acute respiratory distress syndrome. Aviptadil, a vasoactive intestinal peptide supplement, improves breathing and lowers mortality in ARDS patients. This is accomplished through Aviptadil's ability to protect and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis and suppress IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.
Read More On TheGlobal Acute Respiratory Distress Syndrome (ARDS) Market Report Here:
www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report
The Acute Respiratory Distress Syndrome (ARDS) market is segmented -
• By Type: Diagnosis, Treatment
• By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
• By Severity: Mild, Moderate, Severe
• By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the Acute Respiratory Distress Syndrome (ARDS) market.
The Business Research Company's "Global Acute Respiratory Distress Syndrome (ARDS) Market Report 2024" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.
Explore Buying Options For The Acute Respiratory Distress Syndrome (ARDS) Market Report Here:
www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005
The Table Of Content For The Acute Respiratory Distress Syndrome (ARDS) Market Include:
1. Executive Summary
2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics
3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies
4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario
5. Global Acute Respiratory Distress Syndrome (ARDS) Market Size and Growth
…
32. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Benchmarking
33. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market
35. Acute Respiratory Distress Syndrome (ARDS) Market Future Outlook and Potential Analysis
36. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn:in.linkedin.com/company/the-business-research-company
Twitter:twitter.com/tbrc_info
Facebook:www.facebook.com/TheBusinessResearchCompany
YouTube:www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog:blog.tbrc.info/
Healthcare Blog:healthcareresearchreports.com/
Global Market Model:www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases:www.thebusinessresearchcompany.com/press-release.aspx
Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultantsspecialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
